Initial Dose: When MH is suspected, immediate administration of dantrolene is crucial. The initial dose is 2.5 mg/kg intravenously (IV), and it should be given rapidly. This initial bolus dose is essential for halting the progression of the hypermetabolic crisis associated with MH.
Subsequent Bolus Doses: After the initial dose, subsequent bolus doses of dantrolene may be necessary. The Malignant Hyperthermia Association of the United States (MHAUS) recommends redosing dantrolene (2.5 mg/kg) following the initial 2.5 mg/kg bolus as frequently as needed until the patient responds with a decrease in end-tidal carbon dioxide (ETCO2), decreased muscle rigidity, and/or lowered heart rate.
Maximum Dose: In some cases, patients, especially those with generalized rigidity or muscular males, may require higher total doses of dantrolene. The maximum total dose is 10 mg/kg IV. If a patient's response is not observed after a total dose of 10 mg/kg, it may prompt the clinician to reevaluate the diagnosis.
Adverse Effects: It's important to be aware of potential adverse effects of dantrolene, although they are generally well-tolerated. The most common local adverse reaction is venous irritation or thrombosis at the site of administration due to its high pH. Other side effects may include nausea, malaise, lightheadedness, and mild to moderate muscle weakness. Respiratory muscle weakness may occur when larger doses are used, especially in debilitated patients.
Monitoring: Continuous monitoring of the patient's response to dantrolene, along with other vital signs and laboratory values (e.g., blood gases, potassium levels, creatine kinase), is essential during the treatment of MH. Adjustments in dosing or additional interventions may be needed based on the patient's clinical status.
Subsequent Bolus Doses: After the initial dose, subsequent bolus doses of dantrolene may be necessary. The Malignant Hyperthermia Association of the United States (MHAUS) recommends redosing dantrolene (2.5 mg/kg) following the initial 2.5 mg/kg bolus as frequently as needed until the patient responds with a decrease in end-tidal carbon dioxide (ETCO2), decreased muscle rigidity, and/or lowered heart rate.
Maximum Dose: In some cases, patients, especially those with generalized rigidity or muscular males, may require higher total doses of dantrolene. The maximum total dose is 10 mg/kg IV. If a patient's response is not observed after a total dose of 10 mg/kg, it may prompt the clinician to reevaluate the diagnosis.
